Clinical Trials & Research

In a recent article published in Molecules, researchers discuss using oncolytic viruses (OVs) in combination with nanomaterials as a novel approach to cancer treatment. Their combined use has the potential to overcome the limitations of each used individually, such as the side effects of OVs and the inadequate tumoricidal capacity of nanomedicines.  Additionally, they inquired about
0 Comments
TAIPEI, Nov. 21, 2023. Senhwa Biosciences, Inc., a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that U.S. Food and Drug Administration has approved its Phase II IND application of Silmitasertib(CX-4945) to treat patients with community-acquired pneumonia (CAP) caused by viral infection. The trial is a phase
0 Comments
A major new research project will explore the impact of transformational changes to mental health treatment in South America. Community-based care for people with psychosocial disabilities began in the region in the 1960s and 1970s, when a minority of people were moved from large and isolated psychiatric hospitals to residential alternatives in the community. This
0 Comments
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA® (pembrolizumab) in recurrent or progressive enhancing IDH1-mutant diffuse astrocytomas BOSTON, Nov. 18, 2023 /PRNewswire/ — New data from Servier’s clinical development program
0 Comments
Traumatic stress is often followed by adverse post-traumatic neuropsychiatric sequelae (APNS), including post-traumatic stress disorder (PTSD), depression, and somatic or physical symptoms. The underlying pathways remain unclear. A recent study published in Translational Psychiatry examined the potential role of the microbiome-gut-brain axis in this interaction. Study: Association between microbiome and the development of adverse posttraumatic neuropsychiatric
0 Comments
SAN DIEGO, Nov. 20, 2023. Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication. AV5124 is an extremely effective inhibitor of influenza virus
0 Comments
Berlin, November 19, 2023 – OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the recommendation of the study’s Independent Data Monitoring Committee (IDMC) as part of ongoing surveillance which showed an
0 Comments
In a recent article published in Nutrients, researchers evaluate the relationship between 139 dietary factors and the risk of developing colorectal cancer (CRC) using data from 118,210 participants in the United Kingdom (UK) biobank. Study: Diet-Wide Association, Genetic Susceptibility and Colorectal Cancer Risk: A Prospective Cohort Study. Image Credit: aslysun/Shutterstock.com Background CRC is the most common cause of
0 Comments
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland
0 Comments
This year’s European Antibiotic Awareness Day (EAAD) focuses on the targets outlined in the 2023 Council Recommendation to step up efforts in the European Union (EU) against antimicrobial resistance in a One Health approach. Those recommendations formulate the 2023 goal to reduce total antibiotic consumption (community and hospital sectors combined) by 20%, using consumption data
0 Comments
Researchers at the University of Wisconsin–Madison have identified a protein key to the development of a type of brain cell believed to play a role in disorders like Alzheimer’s and Parkinson’s diseases and used the discovery to grow the neurons from stem cells for the first time. The stem-cell-derived norepinephrine neurons of the type found
0 Comments
ORINDA, Calif., Nov. 17, 2023. CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) with the recommended Phase 2 dose (RP2D) of ivaltinostat (ClinicalTrials.gov ID NCT05249101). The RP2D of ivaltinostat (250 mg/m2) was determined by the Safety Review Committee (SRC) following a thorough safety data review from 3 cohorts
0 Comments
Small molecules called immunomodulators can help create more effective vaccines and stronger immunotherapies to treat cancer. But finding the molecules that instigate the right immune response is difficult -;the number of drug-like small molecules has been estimated to be 1060, much higher than the number of stars in the visible universe. In a potential first
0 Comments
5.2% of the global population carry hemoglobin abnormalities, resulting in 300,000 to 400,000 children born with severe hemoglobinopathies annually. Thalassemia, a hereditary hemoglobinopathy, occurs in 4.4 out of every 10,000 live births, and is prevalent in Mediterranean coastal areas, Africa, the Middle East, Southeast Asia, and southern China. To facilitate greater understanding of thalassemia, a
0 Comments
TOKYO, Nov. 15, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating the safety and efficacy of investigational AT132 (resamirigene bilparvovec), an adeno-associated viral vector (AAV) gene replacement therapy designed to deliver a functional
0 Comments
In a recent study published in Scientific Reports, researchers examined the capacity of ensemble learning to anticipate and identify characteristics that impact or contribute to autism spectrum disorder therapy (ASDT) for intervention purposes. Study: On effectively predicting autism spectrum disorder therapy using an ensemble of classifiers. Image Credit: Chinnapong/Shutterstock.com Background ASD is a developmental condition that interferes
0 Comments
The unprecedented coronavirus disease 2019 (COVID-19) pandemic facilitated the rapid development and subsequent deployment of several novel and highly effective vaccines. However, the role of antiviral treatments remained pivotal, especially for certain patient populations incapable of mounting an effective vaccine response or those reluctant to be vaccinated. In a recent review published in the journal Cellular
0 Comments
SAN FRANCISCO, Nov. 16, 2023. Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer’s and other diseases of aging, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for LHP588, the company’s next-generation gingipain inhibitor, for the treatment of P. gingivalis-positive
0 Comments
A number of serious pneumonia cases started to frequently appear in Wuhan, China in December 2019. The number of pneumonia cases was puzzling until the identification of the cause; the novel human coronavirus disease (COVID-19). January 30th, 2020 marked 80,000 reported positive cases around the globe. When it comes to COVID-19, there are still epidemiological
0 Comments
In a recent clinical trial published in JAMA Network Open, researchers from the United States of America (USA) assessed and compared the effectiveness of acupuncture and massage therapy for musculoskeletal pain in 298 patients with advanced cancer. They found that both treatments could reduce pain, fatigue, and insomnia in patients while improving their quality of
0 Comments
Researchers attempt to shed light on possible means of in-hospital spread of SARS-CoV-2. The world is currently experiencing the near-global spread of the novel SARS-CoV-2 virus. Scientists from all over the globe are attempting to gather and process as much information as possible in order to slow or halt the spread of the disease. One
0 Comments
Stand Up To Cancer® (SU2C) today announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer (GEC). The Research Teams, a part of a Dream Team Collective supported by the Torrey Coast Foundation, will unite top researchers from 11 institutions to address critical problems in GEC prevention,
0 Comments
YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. (“RemeGen” or “the Company”), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session by the American College of Rheumatology(RA). According to the abstract, this Phase III, randomized, double-blind study evaluated the
0 Comments
In a recent study published in Scientific Reports, researchers examined the role of specific gut microbes in the secretion of cytokines by peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages (MDM), and human colorectal adenocarcinoma cell line HT-29 cells and its contribution to the pathogenesis of asthma. Study: The potential immunomodulatory role of the gut microbiota in
0 Comments
WHIPPANY, N.J., November 13, 2023–(BUSINESS WIRE)–Bayer today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will work with the FDA on a voluntary withdrawal of the Aliqopa (copanlisib) U.S. New Drug Application for adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Aliqopa
0 Comments